Cover Image
Market Research Report
Product code
1018768

Global Oligonucleotide Therapy Market - 2021-2028

Published: | DataM Intelligence | 180 Pages | Delivery time: 2 business days

Price

Back to Top
Global Oligonucleotide Therapy Market - 2021-2028
Published: July 15, 2021
DataM Intelligence
Content info: 180 Pages
Delivery time: 2 business days
  • ALL
  • Description
  • Table of Contents
Description

Market Overview

The global oligonucleotide therapy market size was valued US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Oligonucleotides are short-chain RNA, or DNA typically generated using automated synthesizers. Oligonucleotides therapy inhibits the expression of certain genes and their development with the raw chemical modified artificial nucleus acids.

Market Dynamics

Technological advancements in antisense technology are expected to drive the growth of the market.

According to the Journal of Biological Chemistry, antisense technology is undertaking to deliver on the broad promise of the technology. Ten RNA-targeted drugs, including eight single-strand antisense drugs (ASOs) and two double-strand ASOs (siRNAs), have now been approved for commercial use. The ASOs in phase 2/3 trials are innovative, delivered by multiple administration routes, and focused on rare and common diseases. Two ASOs are used in cardiovascular outcome studies and several others in very large trials. Interest in the technology continues to grow, and the field has been subject to a significant number of reviews. Thus, from the above statements, the technological advancements in antisense technology are expected to drive the market's growth.

The growing incidence of cancer is expected to drive the growth of the market

According to the American Cancer Society, in 2020, the number of new cancer cases and deaths is estimated at 1.8 million new cancer cases diagnosed and 606,520 cancer deaths in the United States. The rise in cancer cases leads to the demand for novel diagnostics, which is one of the major factors driving the market growth. Moreover, several factors, such as increased pollution and the adoption of a sedentary lifestyle, cause cancer, CVD, diabetes, and autoimmune diseases. The cancer rate has increased drastically in the last few years, and the need for novel therapeutics has increased simultaneously. Oligonucleotide therapeutics are gaining traction as they can produce a new class of nucleic acid probes known as aptamers, which are better probes than monoclonal antibodies. Thus, from the above statements, the growing incidence of cancer is expected to drive the market's growth.

The low number of drug approvals by the FDA is expected to hamper the growth of the market.

Due to the strict standards for manufacturing and high drug efficacy standards set by the regulatory bodies for approval of this therapy and thus increasing the time required for approval and limiting the market's growth. For instance, in January 2020, the market only had 11 drugs approved.

COVID-19 Impact Analysis

The COVID-19 pandemic has caused overwhelming challenges in healthcare worldwide. During such an outbreak, some high-risk groups who require regular follow-ups and long-term management are not met. Many biomedical companies are rising to the challenge and developing COVID-19 diagnostics. Some of these diagnostics have become commercially available for healthcare workers and clinical laboratories in the last few months. However, diagnostic technologies have specific limitations. Oligonucleotide-based therapies are advanced novel interventions to manage various respiratory diseases such as asthma and Chronic Obstructive Pulmonary Disease (COPD). Moreover, during this pandemic, substituting unnecessary clinic visits with virtual clinic services was highly recommended, if possible, without compromising clinical outcomes.

Additionally, it is expected that the market for Oligonucleotide therapy market will undergo impetus growth during the forecast period and continue to witness an excellent growth rate after the end of the pandemic.

Segment Analysis

Antisense Oligonucleotide is expected to hold the largest market share in this market segment.

The antisense oligonucleotide segment is expected to account for the largest share of the market in 2020. This segment's benefit is due to the optimization of enhanced delivery, specificity, affinity, and nuclease resistance with reduced toxicity. Antisense oligonucleotide (ASO) therapies have developed into a prominent class of therapeutics. Moreover, based on such molecules commercially available to the seven drugs, around 160 candidates are under development. For instance, recently approved antisense therapeutics include Viltepso, Vyondys 53 and Waylivra. They target the root cause of diseases at the protein expression level. These disease-modifying invasions have possible applications across a wide spectrum of therapeutic areas, including oncological disorders, neurodegenerative disorders, respiratory disorders, and certain rare genetic disorders.

Additionally, recent advances in antisense oligonucleotide chemistry have enabled the development and synthesis of specialized oligonucleotides, improving safety profiles and better cell targeting capabilities. These advanced variants of antisense oligonucleotide-based therapeutic competitors are assumed to possess the potential to provide to the unmet demand for effective treatment options for diseases that were previously considered difficult to treat. Thus, from the above statements antisense oligonucleotide segment is expected to hold the largest market share.

Neurodegenerative disorders segment is expected to hold the largest market share in this market segment.

The neurodegenerative disorders segment is expected to account for the largest share of the market in 2020. The aged population has an enhanced risk for degenerated nerves, which worsen with time. Alzheimer's disease is the most common neurodegenerative disorder. According to the article(frontiers), in 2020. Alzheimer's disease (AD) is a growing neurodegenerative disease characterized by memory loss, dramatic changes in character and behavior, and difficulty carrying out normal daily activities in the latter stages of the disease.

Moreover, Alzheimer's disease (AD) incidence increases with age and is shown to affect ~10% of people aged 65-75 and 32% of the elderly aged 80 and above. According to the World Health Organization (WHO) incidence of AD is worsening every year. Thus it is assumed that there could be a threefold increase in AD patients by 2050.

Additionally, AD is driven by collecting different forms of amyloid beta-peptide (AB) in the brain leading to neuroinflammation, oxidative stress, mitochondrial dysfunction, dysregulation of enzyme systems, and neuronal death. Therefore, the growth in the aged population increases the number of individuals with Alzheimer's disease. Thus, from the above statements, the neurodegenerative disorders segment is expected to hold the largest market share.

Geographical Analysis

North America region holds the largest market share in the global oligonucleotide therapy market.

North America region is dominating the oligonucleotide therapy market accounted for the largest market share in 2020. The growth is attributed to the presence of the main market leaders, market consolidation, and commercialization of new molecules is expected to boost the market in the forecast period. For instance, Miragen Therapeutics, Inc. agreed to merge with Signal Genetics, Inc for an initial investment of USD 40 million. Through this merger, both the companies expect to develop micro RNA-targeted oligonucleotide clinical products. New molecule application is another strategy the market players use to mark their presence in the oligonucleotide therapy market.

Moreover, Biogen recently received FDA approval for a new drug application for nusinersen. If approved, the antisense oligonucleotides molecule would be the first of its kind to be used for treating spinal muscular atrophy. Thus, the North American region is expected to hold the largest market segment in the forecast period from the above statements.

Competitive Landscape

The oligonucleotide therapy market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Kastle Therapeutics, Sarepta Therapeutics, Pfizer Inc., InteRNA Technologies B.V., Santaris, Akcea Therapeutics, Miragen Therapeuutics Inc., Alnylam Pharmaceuticals Inc.,, Biogen Inc., Ionis Pharmaceuticals Inc. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the oligonucleotide therapy market globally.

Oligonucleotide Therapy Market Key Companies to Watch

Alnylam Pharmaceuticals:

Overview:

Alnylam Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts. The company was founded in 2002, and the company has 18 potential treatments in various development stages in genetic medicine, cardiometabolic disease and infectious hepatic disease. Moreover, the company is focused on discovering, developing, and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Product Portfolio:

Alnylam Pharmaceuticals Inc. on October 15, 2019. announced today that Muthiah (Mano) Manoharan, Ph.D., Senior Vice President of Drug Innovation Chemistry at Alnylam, has been awarded the 2019 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society (OTS).

Why Purchase the Report?

  • Visualize the composition of the oligonucleotide therapy market segmentation by type, application and end user highlighting the key commercial assets and players.
  • Identify commercial opportunities in oligonucleotide therapy market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of oligonucleotide therapy market- level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global oligonucleotide therapy market report would provide an access to an approx. 55market data table, 52 figures and 200pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Oligonucleotide Therapy Market- By Type

  • Antisense Oligonucleotide
  • Aptamer
  • Other

Global Oligonucleotide Therapy Market - By Application

  • Infectious Diseases
  • Oncology
  • Neurodegenerative Disorders
  • Cardiovascular Diseases
  • Kidney Diseases
  • Others

Global Oligonucleotide Therapy Market - By End User

  • Hospitals
  • Research Institutes

Global Oligonucleotide Therapy Market - By Region

  • North America
  • South America
  • Europe
  • Asia
  • Middle East & Africa
Table of Contents
Product Code: DMPH3560

Table of Contents

1. Global Oligonucleotide Therapy Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Oligonucleotide Therapy Market - Market Definition and Overview

3. Global Oligonucleotide Therapy Market - Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by Application
  • 3.3. Market Snippet by End User
  • 3.4. Market Snippet by Region

4. Global Oligonucleotide Therapy Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Technological advancements in antisense technology are expected to drive the growth of the market.
      • 4.1.1.2. The growing incidence of cancer is expected to drive the growth of the market.
    • 4.1.2. Restraints:
      • 4.1.2.1. The low number of drug approvals by the FDA is expected to hamper the growth of the market.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Oligonucleotide Therapy Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. Global Oligonucleotide Therapy Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Oligonucleotide Therapy Market - By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Antisense Oligonucleotide*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Aptamer
  • 7.4. Other

8. Global Oligonucleotide Therapy Market - By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Infectious Diseases*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Oncology
  • 8.4. Neurodegenerative Disorders
  • 8.5. Cardiovascular Diseases
  • 8.6. Kidney Diseases
  • 8.7. Others

9. Global Oligonucleotide Therapy Market - By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
    • 9.1.2. Market Attractiveness Index, By End User Segment
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Research Institutes

10. Global Oligonucleotide Therapy Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Global Oligonucleotide Therapy Market - Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of Key Companies to Watch
  • 11.5. List of Company with disruptive technology
  • 11.6. List of Start Up Companies

12. Global Oligonucleotide Therapy Market- Company Profiles

  • 12.1. Kastle Therapeutics*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Sarepta Therapeutics
  • 12.3. Pfizer Inc.
  • 12.4. InteRNA Technologies B.V.
  • 12.5. Santaris
  • 12.6. Akcea Therapeutics
  • 12.7. Miragen Therapeuutics Inc.
  • 12.8. Alnylam Pharmaceuticals Inc.
  • 12.9. Biogen Inc.
  • 12.10. Ionis Pharmaceuticals Inc.

LIST NOT EXHAUSTIVE

13. Global Oligonucleotide Therapy Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us